

Severe Vision Impairment and Blindness in Hospitalized Patients: A Nationwide Study

Che Harris (✉ charri21@jhmi.edu)

Johns Hopkins University School of Medicine <https://orcid.org/0000-0002-8010-9449>

Scott M Wright

Johns Hopkins University School of Medicine

Research article

Keywords: impairment, blindness, SVI/B, Nationwide Inpatient Sample,

Posted Date: September 8th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-66211/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: Outcomes among hospitalized patients with severe vision impairment or blindness have not been extensively explored. This study sought to determine clinical and resource utilization outcomes in patients with severe vision impairment/blindness (SVI/B).

Methods This was a retrospective study using the Nationwide Inpatient Sample for the year 2017, hospitalized adults with and without severe vision impairment/blindness were compared. Multiple logistic regression and linear analysis were used to evaluate mortality, disposition, length of stay, and hospital charges.

Results: 30,420,907 adults were hospitalized, and among these 37,200 had SVI/B. Patients with SVI/B were older (mean age \pm SEM: 66.4 \pm 0.24 vs. 57.9 \pm 0.09 years, $p < 0.01$), less likely to be female (50% vs 57.7%, $p < 0.01$), and more frequently insured by Medicare (75.7% vs 49.2%, $p < 0.01$). Patients with SVI/B had more comorbidities (Charlson comorbidity score ≥ 3 : 53.2% vs 27.8%, $p < 0.01$). They also had a higher mortality rate (3.9% vs 2.2%; $p < 0.01$). Those with SVI/B were less likely discharged home (adjusted Odds Ratio {aOR} = 0.54, [Confidence Interval (CI) 0.51-0.58]; $p < 0.01$). Hospital charges were not significantly different (adjusted Mean Difference {aMD} = \$247 CI [-\$2,474-2,929]; $p = 0.85$) but length of stay was longer (aMD = 0.5 days CI [0.3-0.7]; $p < 0.01$) for those with SVI/B.

Conclusion: Patients admitted to American hospitals in 2017 who had severe vision impairment or blindness had worse clinical and greater resources utilization. Hospital-based providers should recognize this vulnerable patient population as being at risk for adverse outcomes during hospitalization and determine interventional strategies.

Background

It is estimated that between 3.4–21 million adults in the United States are visually impaired or blind, and up to 80 million have eye diseases that may ultimately lead to blindness (1). Furthermore, the annual economic impact of blindness is estimated to be over 35 billion dollars (2). As the population ages, the number of Americans with blindness is expected to double by the year 2030 (1). As such, an increasing number of patients with blindness will be hospitalized; hospital providers of all disciplines will invariably become progressively more involved in their care.

Unfortunately, few studies have sought to screen for and consider poor vision during hospitalizations when visual disturbances are not related to the chief reason for admission (3). While it has been established that vision impairment is associated with inpatient complications outcomes, such as falls and delirium (4, 5), no US based national study has investigated in-hospital mortality in patients with severe vision impairment or blindness (SVI/B). Morse determined that older Medicare recipients with severe vision loss utilized more healthcare resources compared to those without this disability (6). However, the impact on a broader age range of patients with SVI/B has not been studied on a national level. We used the Nationwide Inpatient Sample (NIS) database for the year 2017, and hypothesized that hospitalized patients with SVI/B would have higher in-hospital mortality, less likely to be discharged home following hospitalization, have longer hospital stays, and greater hospital charges compared to those who were non-visually impaired. Given the worsening obesity epidemic in United States and the uncertain effect it was having on patients admitted who had SVI/B, a subgroup analysis was also carried out to investigate the additive impact of obesity on these same outcome variables.

Methods

Setting / Database

This study used the 2017 NIS database, available through the Agency for Healthcare Research and Quality provided by the Healthcare Cost and Utilization Project (7). NIS is the largest United States based publicly available all-payer inpatient health care database (7). It approximates a 20% stratified sample of US hospital discharges from 46 participating states. The NIS has data for more than 7 million unweighted hospital stays per year. When weighted to represent all admissions, it estimates more than 35 million hospitalizations annually, and represents about 95% of US hospitalizations. Strata include hospital size/volume, teaching status, geographic region, and hospital ownership. Data from 2017 NIS uses the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) coding system for all discharge diagnoses.

Study Population, Patient Characteristics, and Outcomes

All patients ≥ 18 years of age were included in the sample. We then identified selected patients with bilateral severe visual impairment or bilateral blindness as described by their ICD-10 CM codes (eye category 2 through 5 for either eye): <https://www.icd10monitor.com/looking-at-new-icd-10-cm-codes-for-blindness> (updated September 27th 2017). In addition, ICD-10 code H54.0 was also used for bilateral blindness. ICD-10 codes used for our subgroup analysis to study the impact of obesity as a secondary diagnosis on patients with SVL/B was also retrieved (See Supplementary A table for ICD-10 codes and corresponding diagnoses).

Data was collected and adjusted for select patient characteristics including age, gender (male and female only), race (White, Black, Hispanic, Asian or Pacific Islander), insurance, median household income (based on home zip code), and the Charlson comorbidity index. The primary outcome was mortality during hospitalization; secondary outcomes were total hospital charges, length of stay (LOS), and disposition after hospitalization.

Our Institutional Review Board designated this work as being exempt from detailed review (IRB review number: 00257552).

Statistical analyses

Comparisons were examined between patients with SVI/B and the general population without visual impairments using Pearson's χ^2 tests and one-way analysis of variance to test categorical and continuous variables. Analyses were also carried out within the SVI/B patient cohort assessing those with and without obesity. Adjusted odds ratios [aOR] and adjusted mean differences [aMD] from multivariate logistic and linear regression analyses were obtained. Binary outcomes under logistic regression analyses (in-hospital mortality and discharge disposition) were studied. Linear regression was used to study continuous outcome variables (including total hospital charges and LOS). Stata 15.0 statistical software (Stata Corp, College Station, TX) was used and permitted us to account for design complexity (stratification, weighting, and clustering) (7). The p-values for this study were 2 sided and type I error significance level was set at 0.05.

Results

In 2017, 35,769,613 adults ≥ 18 years of age were hospitalized in the United States. From this group, 37,200 patients were severely visually impaired or blind (see Figure). Demographic data is shown in Table 1. SVI/B patients were older (mean age \pm SEM: 66.4 \pm 0.24 vs. 57.9 \pm 0.09 years, $p < 0.01$), less likely to be female (50% vs 57.7%, $p < 0.01$), and a higher proportion were insured by Medicare (75.7% vs 49.2%, $p < 0.01$). Table 2 displays that patients with SVI/B had a greater comorbidity burden (Charlson comorbidity score ≥ 3 : 53.2% vs 27.8%, $p < 0.01$), as well as higher rates of vascular and pulmonary comorbidities.

Table 1
Patient Demographics: Patients with and without blindness from the National Inpatient Sample Database (2017)*

	Patients without Blindness	Patients with Blindness	p-value
Total	30,363,917 (99.8)	37,200 (0.2)	
Age in years , mean \pm SE	57.9 \pm 0.09	66.4 \pm 0.24	< 0.01
Female , n (%)	17,519,980 (57.7)	18,600 (50.0)	< 0.01
Race , n (%)			< 0.01
White	20,404,552 (67.2)	20,832 (56.0)	
Black	4,615,315 (15.2)	9,114 (24.5)	
Hispanic	3,340,030 (11.0)	5,022 (13.5)	
Asian or Pacific Islander	819,825 (2.7)	818 (2.2)	
Insurance , n (%)			< 0.01
Medicare	14,939,047 (49.2)	28,160 (75.7)	
Medicaid	5,799,508 (19.1)	5,056 (14.8)	
Private	8,350,077 (27.5)	3,013(8.1)	
Uninsured	1,214,556 (4.0)	483 (1.3)	
Median income (USD) , n (%)			< 0.01
\$1-\$38,999	9,230,630 (30.4)	14,024 (37.7)	
\$39,000-\$47,999	8,046,438 (26.5)	9,672 (26.0)	
\$48,000-\$62,999	7,105,156 (23.4)	7,551 (20.3)	
\$63,000 or more	5,920,963 (19.5)	5,877 (15.8)	
Hospital Bed size , n (%)			0.14
Small	6,103,147 (20.1)	7,068 (19.0)	
Medium	8,957,355 (29.5)	10,899 (29.3)	
Large	15,273,050 (50.3)	19,158 (51.5)	
Hospital Region , n (%)			< 0.01
Northeast	5,678,052 (18.7)	5,840 (15.7)	
Midwest	6,801,517 (22.4)	7,886 (21.2)	
South	11,933,019 (39.3)	15,438 (41.5)	
West	5,890,599 (19.4)	7,960 (21.4)	
Teaching hospital , n (%)			0.17
Non-teaching, n (%)	3,643,670 (12.0)	4,203 (11.3)	
Teaching, n (%)	26720,247 (88.0)	32,996 (88.7)	

*Analyses used Pearson's χ^2 test and one-way analysis of variance for categorical and continuous variables respectively.

Table 2
Associated Co-morbidities of Patients with and without Blindness

Co-morbidities	Patients without Blindness N (%)	Patients with Blindness N (%)	p-value
Total	30,363,917 (99.8)	37,200 (0.1)	
Charlson comorbidity score			< 0.01
0	11,902,655 (39.2)	5,691 (15.3)	
1	5,860,235 (19.3)	5,914 (15.9)	
2	4,099,128 (13.5)	5,580 (15.0)	
3 or more	8,441,168 (27.8)	19,790 (53.2)	
Opioid use	637,642 (2.1)	446 (1.2)	< 0.01
Tobacco use	5,222,593 (17.2)	3,720 (10.2)	< 0.01
Alcohol use	1,366,376 (4.5)	706 (1.9)	< 0.01
Depression	242,911 (0.8)	334 (0.9)	0.68
Chronic lung disease	4,736,771 (15.6)	5,914 (15.9)	< 0.01
Hypertension	15,880,328 (52.3)	26,226 (70.5)	< 0.01
Diabetes with complications	4,433,131 (14.6)	14,619 (39.3)	< 0.01
Peripheral vascular disease	1,457,468 (4.8)	3,980 (10.7)	< 0.01

Patient Clinical and Resource Utilization Outcomes

Table 3 shows that patients with SVI/B had higher rates of mortality compared to the general population of hospitalized adults (3.9% vs 2.2%; $p < 0.01$). This finding held after adjusting for potential confounders where in-hospital mortality for patients with SVI/B remained higher compared to those without vision impairment (adjusted Odds Ratio (aOR) = 1.2, [Confidence Interval (CI) 1.0-1.4]; $p = 0.01$). Patients with SVI/B were also less likely discharged home (adjusted Odds Ratio (aOR) = 0.54, [Confidence Interval (CI) 0.51–0.58]; $p < 0.01$). Total hospital charges were not significantly different (adjusted Mean Difference (aMD) = \$247 CI [-\$2,474-2,929]; $p = 0.85$) between groups, but LOS was longer (aMD = 0.5 days CI [0.3–0.7]; $p < 0.01$) for those with SVI/B.

Table 3

Differences and odds ratios for in-hospital outcomes in patients with and without blindness ages 18 years and older from the National Inpatient Sample (2017)

Outcome	Patients without Blindness N = 30,363,917	Patients with Blindness N = 37,200	Univariate Mean Difference	(95% CI)	P- value	Multivariate Mean Difference	(95% CI)	P- value
Mean length of stay, days	4.72	6.05	1.33	(1.18–1.48)	< 0.01	0.5	(0.3–0.7)	< 0.01
Mean charge per case, US dollars	53,388	59,900	\$6,512	(4,211–8,811)	< 0.01	\$247	(-2474–2929)	0.85
			Univariate Odds Ratio			Multivariate Odds Ratio		
In-hospital mortality, n (%)	668,008 (2.2)	1,450 (3.9)	1.8	(1.6–2.0)	< 0.01	1.2	(1.0–1.4)	0.01
Discharged to home, n (%)	19,250,723 (63.4)	14,656 (39.4)	0.37	(0.35–0.39)	< 0.01	0.54	(0.51–0.58)	< 0.01

*Variables adjusted for confounders in multivariate analysis include age, gender, race, median household income, insurance and comorbidities measured using the Charlson comorbidity index), hospital bed size, teaching status, urban location, and region.

Subgroup analysis focused on obesity

Among patients with SVI/B, 32,201 (86.5%) were not obese and 4,999 (13.5%) were classified as obese. Patients with obesity were younger (mean age \pm SEM: 61.5 \pm 0.53 vs. 67.2 \pm 0.27 years, $p < 0.01$) and a higher proportion were female (58.8% vs 48.6%, $p < 0.01$). Patients with obesity had higher comorbidities (Charlson comorbidity scores ≥ 3 : 65.0% vs 51.8%, $p < 0.01$). Table 4 shows that obese status was not associated with an altered LOS, odds of mortality, or likelihood of being discharged to home. However, SVI/B patients with obesity had higher total hospital charges compared to those without obesity (mean difference: \$9,821 [CI \$1,375–\$18,268]; $p = 0.02$).

Table 4

Differences and odds ratios for in-hospital outcomes in blind patients with and without obesity ages 18 years and older from the National Inpatient Sample (2017)

Outcome	Non-obese and Blind N = 32,201	Obese and Blind N = 4,999	Univariate Mean Difference	(95% CI)	P- value	Multivariate Mean Difference	(95% CI)	P- value
Mean length of stay, days	6.0	6.4	0.4	(-0.3–1.0)	0.06	0.5	(-0.1–1.2)	0.12
Mean charge per case, US dollars	\$58,882	\$67,456	\$8,574	(1,805 – 15,662)	0.01	\$9,821	(1,375 – 18,268)	0.02
			Univariate Odds Ratio			Multivariate Odds Ratio		
In-hospital mortality, n (%)	1,320 (4.1)	154 (3.1)	0.7	(0.5–1.0)	0.1	0.64	(0.4–1.0)	0.07
Discharged to home, n (%)	12,268 (38.1)	2,154 (43.1)	1.2	(1.0–1.3)	< 0.01	1.0	(0.9–1.2)	0.68

*Variables adjusted for confounders in multivariate analysis include age, gender, race, median household income, insurance and comorbidities measured using the Charlson comorbidity index), hospital bed size, teaching status, urban location, and region.

Discussion

Millions of Americans have severe visual impairment or are blind. As rates continue to climb with the aging of the population, inpatient providers will encounter more patients with this disability and they will be expected to effectively manage this vulnerable population. This study shows that compared to those who are not visually impaired, patients with SVI/B who are hospitalized have higher mortality rates, longer LOS, and are less likely to be discharged to home following the admission. Moreover, among patients with SVI/B, those who were obese had higher total hospital charges than their non-obese counterparts.

A 2013 study from Western Australia discovered that legally blind hospitalized adults had a seven times higher mortality rate compared to patients with normal vision (8). This was carried out using a regional registry; the analysis reviewed over 12,000 hospitalizations of blind adults between

study years 1999 and 2010. In a longitudinal study from 2002–2013 using the Korean National Health Insurance database, Choi also found that those with blindness (> 1200 individuals) also had a higher mortality than patients with normal sight (9). This association held in distinct analyses assessing both older (> 60 years of age) and younger (< 60 years) patients (9). In 2013, the World Health Organization (WHO) launched a global action plan for universal eye health with specific guidance for caring for those with SVI/B (10). These efforts were intended to heighten awareness and escalate the reporting of vision loss in hopes of modifying clinical practice. The current study provides more recent results compared to those from Australia and Korea, while substantiating their findings within a larger cohort. Further, the associations noted among patients hospitalized in the US illustrate that the WHO's concerns about worse healthcare outcomes among those who are blind are still justified.

To explore in-hospital resource utilization, Morse studied two claims databases - Medicare database and Clinformatics DataMart; their objective was to compare the care of older hospitalized patients with and without vision loss (6). The study found that patients with severe vision loss had longer LOS, more readmissions, and higher hospital costs compared to patients without vision loss. Though our study also found that patients with SVI/B had longer LOS, there were not significantly higher hospital charges compared to those without this disability. The differences in the results might be explained by the fact that our patient population was broader, including younger hospitalized adults. Also, if the longer LOS was attributable to time spent on education and coordination of care, the lack of variance in charges accrued over the protracted time span may be linked to Taheri's observations that LOS attributable to the last portion of the hospitalization does not significantly contribute to hospital costs (11). For these very reasons, LOS is not always correlated with hospital costs (12). Given that a significantly higher number of SVI/B patients were discharge to facilities rather than to their homes, it may be reasonable to presume that they did not amass high charges while awaiting placement. By contrast, the cohort of hospitalized SVI/B patients who were obese had significantly higher average charges; this result is similar to other studies that have examined the impact of obesity among those who are hospitalized (13). Future studies may need to target vision information at the time of hospitalization to determine if this would alter the hospitalization or decrease morbidity and mortality.

Several limitations of this study should be considered. First, the NIS is an administrative database wherein data is highly dependent on coding imputations. It is possible that under-coding for SVI/B and obesity may have occurred. Second, the NIS lacks detailed lab data or imaging results, and medications cannot be examined. Thus, an in-depth investigation into the details of our findings was not feasible. Third, special circumstances that might have influenced diagnostic or treatment decisions, such as social factors and patients' preferences, cannot be determined from administrative databases. Lastly, in observational studies there may be unmeasured and unknown confounders that influence outcomes. Observed associations suggest relationships between variables but do not prove causality.

Conclusions

Patients with severe visual impairment or blindness have worse clinical outcomes and higher resources utilization when hospitalized compared to those without this disability. Hospital-based healthcare providers should recognize this vulnerability and consider how to optimally care for and serve this group of patients.

Abbreviations

SVI/B: Severe Vision Impairment/Blindness

NIS: Nationwide Inpatient Sample

SEM: Standard Estimated Mean

aOR: adjusted Odds Ratio

aMD: adjusted Mean Difference

CI: Confidence Interval

ICD-10-CM: International Classification of Diseases, 10th Revision, Clinical Modification

US: United States

TX: Texas

LOS: Length of Stay

WHO: World Health Organization

Declarations

Ethics declarations

The study was not submitted for research ethics approval as the activities described were conducted as part of the National Inpatient Sample (NIS), which is part of the family of databases and software tools developed for the Healthcare Cost and Utilization Project (HCUP) and uses de-identified data collected from hospitalized patients. The study activities obtained from NIS are exempt from the Johns Hopkins' Institutional Review Board and do not require informed consent. For additional details, please refer to the following website links: https://www.hopkinsmedicine.org/institutional_review_board/guidelines_policies/guidelines/exempt_research.html; https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=83cd09e1c0f5c6937cd9d7513160fc3f&pid=20180719&n=pt45.1.46&r=PART&ty=HTML#se45.1.46_1104.

Consent for Publication

Not applicable. All data using the National Inpatient Sample is de-identified.

Availability of data and materials

Researchers should readily be able to purchase the same databases we did to conduct research here: <https://www.distributor.hcup-us.ahrq.gov/Databases.aspx>. The authors did not have special access privileges to the NIS databases. Contact information for further guidance on purchase and download at vog.qrha@rotubirtsiDPUCH.

Competing Interests

The authors declare that they have no competing interests (financial and non-financial).

Funding

Dr. Wright receives support as the Anne Gaines and G. Thomas Miller Professor of Medicine through the Johns Hopkins Center for Innovative Medicine.

Acknowledgements

Not applicable

References

1. Centers for Disease Control and Prevention. https://www.cdc.gov/visionhealth/basic_information/vision_loss.htm. Accessed July 13, 2020.
2. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. *Ophthalmol*2006;124(12):1754–1760.
3. Press VG, Matthiesen MI, Ranadive A, Hariprasad SM, Meltzer DO, Arora VM. *Insights into inpatients with poor vision: A high value proposition*. *J Hosp Med*. 2015 May;10(5):311-3.
4. Oliver D, Daly F, Martin FC, McMurdo ME. Risk factors and risk assessment tools for falls in hospital in-patients: a systematic review. *Age Ageing*. 2004;33(2):122–30.
5. Inouye SK, Zhang Y, Jones RN, Kiely DK, Yang F, Marcantonio ER. Risk factors for delirium at discharge: development and validation of a predictive model. *Arch Intern Med*. 2007;167(13):1406–13.
6. Morse AR, Seiple W, Talwar N, Lee PP, Stein JD. Association of Vision Loss With Hospital Use and Costs Among Older Adults. *JAMA Ophthalmol*. 2019 Jun 1;137(6):634-640.
7. National Inpatient Sample. <https://www.hcup-us.ahrq.gov/nisoverview.jsp>. Accessed July 15, 2020.
8. Crewe JM, Spilsbury K, Morlet N, Morgan WH, Mukhtar A, Clark A, Semmens JB. Health Service Use and Mortality of the Elderly Blind. 2015 Nov;122(11):2344-50.
9. Choi HG, Lee MJ, Lee SM. Mortality and causes of death in a population with blindness in Korea: A longitudinal follow-up study using a national sample cohort. *Sci Rep*. 2020 Mar 17;10(1):4891.
10. World Health Organization. Universal Eye Health. A Global Action Plan 2014-2019. https://www.who.int/blindness/AP2014_19_English.pdf. Accessed July 15, 2020.
11. Taheri PA, Butz DA, Greenfield LJ. Length of stay has minimal impact on the cost of hospital admission. *J Am Coll Surg*. PMID: 10945354.

12. Hirsch R. Length of Stay: Understanding its Shortcomings. 2018 Nov 7. <https://www.racmonitor.com/length-of-stay-understanding-its-shortcomings>. Accessed July 15, 2020.

13. Zizza C, Herring AH, Stevens J, Popkin BM. Length of hospital stays among obese individuals. *Am J Public Health* 2004; 94: 1587-1591.

Figures




Figure 1

Patient identification flow diagram with data from 2017

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryTableA.docx](#)